Speaker's Highlight

• Don Sin University of British Columbia, St. Paul Hospital (Canada)
  Kenneth R. Chapman Toronto General Hospital Research Institute (Canada)
• Parameswaran Nair McMaster University (Canada)
  Carolyn Calfee UCSF (U.S.A.)
• Gregory P. Downey University of Colorado School of Medicine (U.S.A.)
  David A. Schwartz University of Colorado School of Medicine (U.S.A.)
• Neil Schluger Tuberculosis Control Branch, California Department of Public Health (U.S.A.)
  Nick Kim Critical Care & Sleep Medicine, University of California San Diego (U.S.A.)
• Nicola Hananiah Baylor College of Medicine (U.S.A.)
  Jae-Joon Yim Seoul National University College of Medicine (Republic of Korea)
• Koichiro Asano Tokai University School of Medicine (Japan)
  Diahn-Warng Perng Taipei Veterans General Hospital (Taiwan)
• Konstantinos Kostikas University of Ioannina (Greece)
  Karin Klooster University Medical Center Groningen (Kingdom of the Netherlands)

• The Gut-Lung Axis And The Future Of Respiratory Care

  The lungs and gastrointestinal tract are separated by anatomy but closely linked through immune signaling, microbial activity, and systemic metabolism. This relationship, known as the gut-lung axis, is reshaping how researchers understand respiratory health and chronic airway disease.

  The intestinal microbiome influences immune development and helps regulate inflammation throughout the body. In return, respiratory infections, medications, diet, and environmental exposures can alter gut microbial communities. These two-way interactions may help explain why gastrointestinal health is increasingly relevant to asthma, chronic obstructive pulmonary disease (COPD), respiratory infection, and inflammatory lung conditions.

  For respiratory medicine, the subject creates a bridge between pulmonology, microbiology, immunology, nutrition, and preventive care. It also encourages clinicians and researchers to look beyond the airway itself when investigating disease susceptibility, treatment response, and long-term outcomes.

  A biological conversation between gut and lungs

  The gut contains trillions of microorganisms, including bacteria, viruses, fungi, and other microbial species. Together, they contribute to digestion, nutrient production, epithelial barrier function, and immune education. Short-chain fatty acids, produced when gut bacteria ferment dietary fiber, can influence immune cells and inflammatory pathways far beyond the gastrointestinal tract.

  Signals also travel in the opposite direction. Inhaled pollutants, cigarette smoke, viral infections, and systemic inflammation can affect intestinal permeability and microbial composition. This communication involves circulating metabolites, cytokines, immune cells, and the movement of microbial products through the bloodstream.

  A balanced microbiome may support appropriate immune tolerance, while dysbiosis can contribute to excessive or poorly controlled inflammation. The precise definition of a “healthy” microbiome remains uncertain, because age, geography, diet, genetics, medication use, and disease status all influence microbial profiles.

  Microbiome development and respiratory vulnerability

  Early life may be a particularly important period for gut-lung interactions. Birth conditions, breastfeeding, antibiotic exposure, diet, and childhood infections can influence microbiome development and immune maturation. Research has associated certain early-life microbial patterns with later asthma risk, although these relationships are complex and do not establish that one factor directly causes another.

  Antibiotics illustrate the clinical tension clearly. They can be essential for treating bacterial infections, yet unnecessary or repeated use may reduce microbial diversity and change immune regulation. This does not mean antibiotics should be withheld when indicated; it highlights the importance of antimicrobial stewardship and careful prescribing.

  Dietary fiber, fermented foods, and overall nutritional quality may support microbial diversity, but dietary advice must be individualized. Supplements marketed as microbiome solutions often have limited evidence, and probiotics do not produce identical effects in every person or disease setting.

  Respiratory conditions connected to the gut

  Asthma research has explored links between intestinal dysbiosis, allergic sensitization, airway hyperresponsiveness, and immune imbalance. Some studies suggest that microbial metabolites may affect regulatory T cells and allergic inflammation. However, asthma is biologically diverse, so a single microbiome signature is unlikely to explain every phenotype.

  In COPD, smoking, age, reduced physical activity, nutritional status, medications, and frequent exacerbations may all influence the gut microbiota. Gut barrier changes and systemic inflammation could contribute to disease progression or recovery, but researchers are still determining whether microbiome alterations are a cause, a consequence, or both.

  The gut-lung axis is also relevant to respiratory infections. Microbial metabolites may strengthen antiviral defenses and improve immune readiness, while severe infection, hospitalization, and antibiotic exposure can disrupt intestinal ecology. In interstitial lung disease and other immune-mediated disorders, the same communication pathways are being examined as potential contributors to persistent inflammation.

  Comparing pathways across respiratory disease

  The clinical meaning of gut-lung research differs by condition. Some findings involve susceptibility, while others relate to exacerbation frequency, treatment response, or recovery after infection. The following overview summarizes areas of active investigation rather than established diagnostic rules.

  Respiratory condition	Gut-lung pathway under study	Potential clinical relevance
  Asthma	Microbial metabolites, immune tolerance, and allergic inflammation	Risk profiling and prevention research
  COPD	Dysbiosis linked with smoking, systemic inflammation, and exacerbations	Supportive care and recovery biomarkers
  Respiratory infection	Microbiome effects on antiviral and antibacterial immunity	Infection severity and resilience
  Interstitial lung disease	Immune signaling and intestinal barrier function	Disease phenotyping and therapeutic targets
  Cystic fibrosis	Antibiotics, nutrition, mucus disease, and microbial disruption	Personalized antimicrobial and nutritional care

  These connections should be interpreted carefully. Microbiome studies often involve small samples, different laboratory methods, and associations that may not translate directly into patient benefit. Standardized sampling, longitudinal follow-up, and clinically meaningful outcomes are essential before routine testing can be recommended.

  From association to clinical evidence

  Modern sequencing can identify microbial DNA, while metabolomics measures compounds produced or modified by microbes. Together, these methods provide a richer picture than bacterial counts alone. Still, detecting a microbial pattern does not prove that it drives respiratory disease.

  Future studies need to combine microbiome data with lung function, imaging, inflammatory markers, medication exposure, diet, and environmental information. Randomized trials of dietary interventions, targeted probiotics, prebiotics, postbiotics, or microbiome-preserving treatment strategies will be especially important.

  Researchers must also account for confounding factors. Smoking, obesity, socioeconomic conditions, healthcare access, corticosteroids, proton pump inhibitors, and recent antibiotics can all influence both the microbiome and respiratory outcomes. Collaboration across respiratory and gastrointestinal specialties can improve study design and interpretation.

  Translating research into respiratory care

  The gut-lung axis should complement, rather than replace, established respiratory management. Vaccination, smoking cessation, inhaled therapy, pulmonary rehabilitation, nutritional assessment, and prompt treatment of exacerbations remain central to patient care. Microbiome research may eventually help refine these approaches for specific patient groups.

  Clinicians can already support gut and lung health through practical, evidence-based measures. Reviewing unnecessary medications, encouraging a diverse diet when medically appropriate, addressing malnutrition, and using antibiotics responsibly may benefit overall health without overstating what microbiome science can currently deliver.

  Key priorities for clinicians, researchers, and conference delegates include:

  • Define reproducible microbiome and metabolite markers for distinct respiratory phenotypes.
  • Use longitudinal studies to separate causes of disease from effects of treatment or hospitalization.
  • Include diet, antibiotic exposure, smoking, geography, and socioeconomic factors in research models.
  • Test microbiome-targeted interventions in well-designed clinical trials with patient-centered outcomes.
  • Build multidisciplinary partnerships between pulmonology, gastroenterology, immunology, nutrition, and microbiology.

  A shared direction for respiratory research

  Understanding the gut-lung axis expands the respiratory field from isolated organs to interconnected biological systems. It may reveal why patients with apparently similar lung disease experience different levels of inflammation, infection susceptibility, and treatment response.

  At APSR 2022 and related medical congress discussions, this area offers an opportunity to connect laboratory discovery with clinical priorities. Exploring microbial ecology, immune pathways, nutrition, and personalized medicine can help shape more precise approaches to respiratory disease.

  Continue exploring the science, follow emerging clinical evidence, and engage with experts working across respiratory and gastrointestinal medicine to help advance the next generation of patient-centered care.

  Richard Russell Nuffield Department of Clinical Medicine, University of Oxford (United Kingdom)
• Mona Bafadhel King’s College London (United Kingdom)
  David Jackson Guy’s and St Thomas’ Hospital, King’s College London (United Kingdom)
• James Chalmers University of Dundee (United Kingdom)
  David Price University of Aberdeen (United Kingdom)